204P Use of trastuzumab-deruxtecan in women with gynaecological malignancies

Trastuzumab-Deruxtecan (TDXd) is an antibody-drug-conjugate (ADC) that is already routinely used to treat breast and gastric cancer as well as NSCLC. Data from the DESTINY-PanTumor02 study support its use in gynaecological tumors expressing the HER2 receptor (IHC 2+/3+).

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108142
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

204P Use of trastuzumab-deruxtecan in women with gynaecological malignancies

A Traut, M Bommert, M Moubarak, P. HARTER et al.
ESMO Open
HER2/EGFR in Cancer Research
article

204P Use of trastuzumab-deruxtecan in women with gynaecological malignancies

A Traut, M Bommert, M Moubarak, P. HARTER, T. Westermann, F. Temizel- Kanbur, M. Schemionek, M. Pruss, J. Welz, S. Kaiser, A.N. Strojna, E. Karabeg
article en

Abstract

Trastuzumab-Deruxtecan (TDXd) is an antibody-drug-conjugate (ADC) that is already routinely used to treat breast and gastric cancer as well as NSCLC. Data from the DESTINY-PanTumor02 study support its use in gynaecological tumors expressing the HER2 receptor (IHC 2+/3+).

ESMO OpenVol. 11
Kliniken Essen-Mitte (DE)
Good health and well-being
Openalex Percentile: Top 8%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.